Enbrel Near Psoriasis User Fee Goal; Amgen Looking At "Step Down" Dosing
This article was originally published in Pharmaceutical Approvals Monthly
Phase III psoriasis data for Amgen’s Enbrel show significant efficacy for a "step down" regimen combining initial loading doses of the tumor necrosis factor inhibitor with half-dose therapy over three months.
You may also be interested in...
Immunex's TNF inhibitor Enbrel (etanercept) receives approval Jan. 16 for a new indication to reduce "signs and symptoms of active arthritis in patients with psoriatic arthritis." Enbrel can be used as monotherapy or together with methotrexate. Enbrel also gained clearance for multiple administrations from the same vial, a shelf life of 14 days compared to the previous six hours, and 24-month efficacy data on rheumatoid arthritis. Psoriatic arthritis patients will be enrolled in the Enbrel access program until manufacturing capacity is expanded. The company had estimated its Rhode Island plant could produce the agent by October, but Immunex's new owner Amgen projects a January 2003 start dat
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011